Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-JMJD6, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
JMJD6 also known as Jumonji Domain Containing 6 or PSR (Phosphatidylserine Receptor) is a protein with a molecular mass of approximately 47 kDa. It functions mechanically as a 2-oxoglutarate- and Fe(II)-dependent oxygenase. This protein resides in the nucleus and cytoplasm with a higher expression in the thymus kidney heart and testis. JMJD6 gets involved in demethylating histones and splicing factors playing a role in gene regulation.
Biological function summary
JMJD6 influences gene expression and mRNA splicing processes. It participates in histone arginine demethylation affecting chromatin structure and transcriptional activity. JMJD6 is not known to be part of a larger protein complex but interacts with RNA splicing factors and chromatin modifiers. Its demethylase activity can alter the epigenetic landscape which makes it a vital part of cellular response and differentiation processes.
Pathways
JMJD6 is linked to the regulation of gene expression and RNA processing pathways. It modulates the transcriptional networks by its demethylase activity affecting how genes are turned on or off. JMJD6 often associates with nuclear receptors and splicing proteins such as SF3B1 integrating within the larger network of gene expression controllers and RNA splicing machinery. These interactions place JMJD6 at a critical juncture in gene expression regulation and RNA maturation.
JMJD6 has connections with cancer and autoimmune diseases. Its role in gene regulation and splicing implicates it in cancer progression often in link with prostate cancer. Abnormal JMJD6 expression can lead to disrupted gene patterns contributing to tumor growth. Additionally its alteration has associations with autoimmune diseases where its interaction with histone-modifying proteins like HDAC affects the immune response. These relationships highlight JMJD6's involvement in disease states marking it as a target of interest in research for therapeutic interventions.
